It is a link for moving within the page.

  1. HOME
  2. Pharmaceutical Business
  3. Our Business

Pharmaceutical BusinessOur Business

Providing breakthrough treatments
for patients around the world

From mental health conditions to neurological disorders

In the central nervous system (CNS) field, building on the success of our globally recognized antipsychotic drug ABILIFY, in 2013 we launched ABILIFY Maintena, a once-monthly, extended-release antipsychotic injection, in the U.S. and it is now sold in over 50 countries.
REXULTI, a new antipsychotic drug approved by the FDA in the U.S. for the treatment of schizophrenia and an adjunctive treatment for major depressive disorder, was launched in 2015. It subsequently revived regulatory approval for use in schizophrenia in other countries, including in Japan and Europe in 2018, and is now sold in approximately 60 countries worldwide.
Avanir Pharmaceuticals in the U.S., acquired by Otsuka in 2015, markets in the U.S. NUEDEXTA, a treatment for the neurologic disease pseudobulbar affect (PBA). Avanir is also developing agents for treating symptoms of Alzheimer's type dementia and Parkinson's disease.

Otsuka's therapeutic drugs around the world

In the field of oncology, Busulfex, a conditioning agent prior to bone marrow transplantation in blood cancer, is now available in over 50 countries through Otsuka Pharmaceutical and its partners. It has become a standard treatment replacing radiotherapy within the bone marrow transplantation regimen.
Otsuka also signed an agreement with ARIAD Pharmaceuticals* to commercialize ARIAD's treatment for resistant and intolerant chronic myeloid leukemia in ten Asian countries and regions including Japan, and to fund future clinical trials in those countries. Sales in Japan began in 2016.

  • Acquired by Takeda in 2017

Otsuka Pharmaceutical has implemented the Otsuka Global Patient Access Support Policy to expand and improve patient access to medical care, including drug treatment.
The Otsuka Patient Assistance Program (OPAP) was created in 2019 to enable access to ICLUSIG tablets for patients with some types of leukemia in Asian countries and regions.
The program’s aims are inclusive - to increase access to medical care and improve treatment success by providing ICLUSIG, and if necessary, financial support to patients who cannot afford medical care due to insufficient insurance reimbursement or financial reasons.

In the cardiovascular field, the vasopressin V2 receptor antagonist Samsca has achieved good penetration in medical settings thanks to the new value and utility it provides. In 2014, the world's first approval of a treatment for autosomal dominant polycystic kidney disease (ADPKD), an intractable disease with no treatments until now, was obtained for Samsca in Japan. Outside of Japan, it is sold under the global product names JINARC / JYNARQUE. Samsca / JINARC / JYNARQUE is now available in over 40 countries.

In the field of ophthalmology several drugs are available, including the dry-eye treatment Mucosta ophthalmic suspension and the antiglaucoma and anti-intraocular hypertension drugs Mikelan LA, and Mikeluna combination ophthalmic solution.
(As of August 2021)

Therapeutic areas

Central Nervous System

Aiming for the social reintegration of patients with psychiatric and neurological disorders.


Otsuka Pharmaceutical tackles leukemia and other blood cancers.

Cardiovascular and Renal areas

Pursuing the unlimited potential of a single chemical structure.


Living with tuberculosis.


Helping people who suffer from eye diseases worldwide.

By choosing to tackle unaddressed medical needs, we put ourselves on the path to creating new therapeutic approaches and unprecedented drugs. Our researchers are committed to continuing to take the road less travelled, to develop solutions that only we can create.

Otsuka Pharmaceutical collaborates actively with leading-edge academia and venture companies, in addition to using conventional drug discovery methods. This open sharing of ideas enables us to develop unique compounds.